ORTHOPEDIATRICS CORP (KIDS)
Health Care · pediatric medical devices · NASDAQ
The only global medical device company dedicated exclusively to the specialized, often neglected needs of children with orthopedic conditions.
What ORTHOPEDIATRICS CORP does
OrthoPediatrics is a global medical device company that designs, develops, and markets a comprehensive portfolio of implants, instruments, and specialized braces for pediatric orthopedic conditions. The company operates through three primary segments—trauma and deformity correction, scoliosis, and sports medicine—and manages an extensive network of orthotic and prosthetic (O&P) clinics in the United States. It utilizes both a direct sales force and a global network of independent sales agencies and distributors to serve pediatric hospitals and clinics.
Recent developments
OrthoPediatrics raised its 2026 full-year revenue guidance to $265.0–$269.0 million, reflecting 12-14% growth. The company also announced an exclusive distribution agreement with OSSIO to bring metal-free fixation technology to U.S. children's hospitals.
From ORTHOPEDIATRICS CORP's filing of 2026-08-05.
Themes: pediatric orthopedics, trauma & deformity correction, scoliosis treatment, sports medicine, orthotic & prosthetic clinics, medical device innovation
Fundamentals
- Price$23.84 as of 2026-10-21 close
- Market cap$622M as of 2026-08-04 (share count; price 2026-10-21)
- 1-year return+33.1% 2025-10-21 close $17.91 → 2026-10-21 close $23.84
- P/En/a negative earnings
- Net margin-16.8% FY2025, SEC XBRL
- Gross margin+73.1% FY2025, SEC XBRL
- ROE-11.4% FY2025, SEC XBRL
- ROICn/a No figure: its pre-tax income was zero or negative, so there is no tax rate to apply.
- Debt / equity0.30 borrowings, leases excluded / equity — 10-Q/10-K balance sheet 2026-06-30
- Revenue growth (YoY)+15.4% FY2025, SEC XBRL
- Revenue CAGR (3y)+24.6% SEC XBRL
- Beta0.98 as of 2026-09-02
- Last reported earnings2026-08-04 SEC EDGAR Form 8-K (Item 2.02)
How KIDS compares in its sector
- net profit marginmiddle range 430 covered Health Care peers, as of 2026-09-02
- operating marginmiddle range 417 covered Health Care peers, as of 2026-09-02
- gross marginmiddle range 189 covered Health Care peers, as of 2026-09-02
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-02
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Dividend coverage
Not assessed — last reported dividend predates the accounts. The most recent fiscal year in which KIDS reported a dividend payment is FY2017, while its reported financial statements run through FY2025. Coverage is therefore not assessed for the latest year — an FY2017 ratio would not describe KIDS today.
Coverage is derived from reported SEC EDGAR XBRL figures, comparing dividends paid against net income and free cash flow for the SAME fiscal year. It is not shown here because the latest fiscal year with a reported dividend payment (FY2017) is older than the latest year of reported financial statements (FY2025), so any ratio would describe an out-of-date year. Informational only — not financial advice.
Quarterly results
| Quarter | Revenue | Gross profit | Operating income | Net income | Diluted EPS | Operating cash flow | Capex |
|---|---|---|---|---|---|---|---|
| Q2 FY2026 2026-06-30 | $71M | $52M | -$4M | -$7M | -$0.30 | $928000† | $4M† |
| Q1 FY2026 2026-03-31 | $59M | $43M | -$8M | -$11M | -$0.45 | -$3M | $2M |
| Q4 FY2025 2025-12-31 | $62M† | $45M† | -$8M† | -$10M† | -$0.43† | $10M† | $599000† |
| Q3 FY2025 2025-09-30 | $61M | $45M | -$9M | -$12M | -$0.50 | -$581000† | $3M† |
| Q2 FY2025 2025-06-30 | $61M | $44M | -$11M | -$7M | -$0.30 | -$10M† | $3M† |
| Q1 FY2025 2025-03-31 | $52M | $38M | -$11M | -$11M | -$0.46 | -$4M | $4M |
| Q4 FY2024 2024-12-31 | $53M† | $36M† | -$14M† | -$16M† | -$0.70† | -$4M† | -$262000† |
| Q3 FY2024 2024-09-30 | $55M | $40M | -$6M | -$8M | -$0.34 | -$10M† | $1M† |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$17M
- Short-term investments$29M
- Total debt$102M borrowings only; leases excluded
- Net debt$56M total debt − cash − short-term investments
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How ORTHOPEDIATRICS CORP looks technically
ORTHOPEDIATRICS CORP (KIDS) is trading 23.8% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 78 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 14, below the 25 that marks a real trend), though buyers have been pushing harder than sellers lately — pressure, not a trend. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 62, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 2 trading days ago (its momentum flipped positive). It just made a new 20-day high, its first since 2026-08-26, pushing above its recent trading range. Trading volume is running unusually high — about 2.5× its 30-day average, a sign of heightened interest.
Trend
8
| Distance from the 200-day | it is trading 23.8% above its 200-day average, the long-term trend line — a longer-term uptrend | +23.8% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $23.07 | $23.07 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $19.26 | $19.26 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 12 calendar days ago — the swings before that are what the structure reading is measured on | 12 sessions |
| Wave structure | its recent swings can be read as a completed three-part downward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes below 21.26. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave downward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 78 trading days ago — a "golden cross", a bullish long-term signal | 78 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 14, below the 25 that marks a real trend), though buyers have been pushing harder than sellers lately — pressure, not a trend | 14.4 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 62, neither overbought (above 70) nor oversold (below 30) | 61.7 |
|---|---|---|
| Position in its 14-day range | it is trading right at the top of its 14-day range ($21.26 to $23.85) — its "stochastic" reading is 100 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 99.6 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 2 trading days ago (its momentum flipped positive) | 2 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $26.74 | $26.74 |
|---|---|---|
| From the 52-week high | it is 10.8% below its 52-week high (its highest price of the past year) | -10.8% |
| Above the 52-week low | it is 65.3% above its 52-week low (its lowest price of the past year) | +65.3% |
| Below the 52-week high | it is 10.8% below its highest point of the past year | 10.8% |
| Since a 20-day breakout | it just made a new 20-day high, its first since 2026-08-26, pushing above its recent trading range | 1 session |
| Since a 55-day breakout | it made a new 55-day high about 45 trading days ago | 45 sessions |
| All-time high | its highest closing price on record is $73.91 (set on 2021-11-05) | $73.91 |
| Given back of the 52-week move | over the past year its closes ranged ($14.64 to $26.50), and it has given back roughly a quarter of its rise from last year’s low — 22% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $18.79 to $19.17. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 22.4% |
| From the all-time high | it is 67.7% below its all-time high | -67.7% |
| Nearest price level | it is trading 0.9% above a support level at $23.63 — a price it turned at three times since 2025-05-12, most recently on 2026-09-16. Since 2024-10-21 it has 11 such levels below the current price and 4 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -0.9% |
| All-time low | its lowest closing price on record is $14.00 (set on 2018-04-03) | $14.00 |
| Above the all-time low | it is 70.3% above its all-time low | +70.3% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 86% of it) | 14th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.788 between its high and its low — about 3.3% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.788 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $21.31 and $23.52 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $21.31 – $22.41 – $23.52 |
| Typical daily range (% of price) | its price moves about 3.3% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 3.3% |
| Stretch from the 200-day average | it is trading 5.8 daily ranges above its 200-day average price (23.8% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 5.8 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is running unusually high — about 2.5× its 30-day average, a sign of heightened interest | 2.50× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
3
| Since a doji | 8 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 8 sessions ago |
|---|---|---|
| Since a bullish engulfing | 5 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 5 sessions ago |
| Since a bearish engulfing | 3 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 3 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-10-21 at essentially the same price it closed at the session before — no meaningful overnight gap | -0.1% |
|---|---|---|
| Gap filled | a 5.8% gap up opened on 2026-08-05 has been "filled" 54 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 54 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 3 sessions in a row, a +8.61% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 3 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 6.7 percentage points (the stock gained 6.7% while the market lost 0.1%) | +6.7% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 19.0 percentage points (the stock gained 22.3% while the market gained 3.3%) | +19.0% |
| vs market, 6 months | over the past 6 months this stock beat the market by 36.9 percentage points (the stock gained 46.7% while the market gained 9.8%) | +36.9% |
| vs market, 12 months | over the past 12 months this stock beat the market by 18.0 percentage points (the stock gained 33.1% while the market gained 15.2%) | +18.0% |
Signal agreement
2
| Bullish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 3.1% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-15 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 3.0% of the share price. | +3.1% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 21% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $19.77 — a volume-weighted average of daily closes over 199 sessions, not a true tick-by-tick VWAP. | +20.6% |
|---|---|---|
| Vs the average paid since it last reported | the price is 3% above the average price paid since it last reported on 2026-08-04 (its 8-K), so the typical buyer over that stretch is showing a gain. That average is $23.13 — a volume-weighted average of daily closes over 56 sessions, not a true tick-by-tick VWAP. | +3.1% |
Price levels it has turned at before
KIDS last closed at $23.84 on 2026-10-21. Since 2024-10-21 it has turned at 11 prices below its last close and 4 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $23.63 | Support | 0.9% below the last close | turned there three times · 2025-05-12 to 2026-09-16 |
| $23.04 | Support | 3.4% below the last close | turned there three times · 2025-02-07 to 2026-10-06 |
| $22.37 | Support | 6.2% below the last close | turned there five times · 2024-11-15 to 2025-06-12 |
| $25.41 | Resistance | 6.6% above the last close | turned there twice · 2024-10-29 to 2025-02-14 |
| $26.23 | Resistance | 10.0% above the last close | turned there three times · 2025-03-13 to 2025-04-02 |
| $26.94 | Resistance | 13.0% above the last close | turned there twice · 2024-12-04 to 2026-08-20 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part downward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes below $21.26.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
This reading has stood for 21 trading days, since 2026-09-23.
Read from daily closes as of 2026-10-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Trading above the 50-day moving average · Unusually heavy trading volume · Broke out to a new 20-day high · Broke out to a new 20-day high on heavy volume · MACD just crossed bullish (12/26/9) | Learn: moving average · golden cross · adx · rsi · macd · breakout · volume and relative volume
Based on daily closing prices as of 2026-10-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Mean price target$27.22 range $22.00 – $35.00; median $25.00
Analyst estimates, as of 2026-10-17. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for KIDS
- Consensus EPS estimate-$0.215 next reporting period, as of 2026-10-17
- Estimate change, 30 days$0.00 from -$0.215, on 2026-09-12, 35-day window
- Readings revised upward0% of 9 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Significant dependence on consigned inventory in hospitals which requires substantial upfront capital.","Unpredictable impacts of health emergencies or pandemics on the volume of elective pediatric surgeries.","Risk associated with integrating multiple small-scale acquisitions and managing rapid business expansion."]
What changed in the latest 10-Q
AI-assisted comparison of KIDS's 10-Q filed 2026-08-05 against the prior one filed 2026-05-01.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-08-05) states the company currently markets 'over 90' surgical and specialized bracing systems; older filing (2026-05-01) stated 'nearly 90'.
- Newer filing (2026-08-05) states independent sales agencies employ '240' sales representatives; older filing (2026-05-01) stated '230'.
- Newer filing (2026-08-05) states the company has impacted the lives of '1,382,000' children since inception; older filing (2026-05-01) stated '1,336,000'.
- Newer filing (2026-08-05) states consignment sales accounted for approximately 60% of total net sales 'For the six months ended June 30, 2026'; older filing (2026-05-01) stated this for 'the three months ended March 31, 2026'.
- Removed:
- Older filing (2026-05-01) included the text 'in developing countries' after 'provide access to medical care for children' in the World Pediatric Project bullet point; this phrase continues beyond the truncation point in the newer filing text.
- Reworded:
- Newer filing (2026-08-05) describes the SEC as 'the Securities and Exchange Commission ("SEC")'; older filing (2026-05-01) used 'the SEC' without spelling out the full name in the same sentence.
- Notes:
- The newer filing source text is truncated after 'provide access to medical care for childre' and the older filing source text is truncated after 'We ar', so the comparison of the Social Impact section bullet points is incomplete.
- Only the Management's Discussion & Analysis section was provided for comparison; changes in other sections were not assessed.
Risk Factors
- Added:
- Newer filing (2026-08-05) describes the issuance of 80,873 shares of common stock on April 1, 2026, valued at $1,398,666, in connection with the purchase of a UK medical device distributor, under Section 4(a)(2) of the Securities Act.
- Newer filing (2026-08-05) describes the issuance of 153,430 shares of common stock on May 1, 2026, with an aggregate value of approximately $2,398,000, to members of MedTech Concepts LLC in lieu of the third anniversary payment under the MedTech Purchase Agreement.
- Removed:
- Older filing (2026-05-01) states "None" under "Sale of Unregistered Securities."
- Reworded:
- Newer filing (2026-08-05) states no director or officer adopted or terminated a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement "during the six months ended June 30, 2026"; older filing (2026-05-01) stated "during the three months ended March 31, 2026."
- Newer filing (2026-08-05) omits Exhibit 10.1 (Credit Agreement and Guaranty dated August 5, 2024) and Exhibit 10.2 (First Amendment to Credit Agreement and Guaranty dated March 31, 2026) from the exhibit list; older filing (2026-05-01) includes both exhibits.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 21 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-17. The 5 days since 2026-10-17 have not been checked yet.
- Last 90 days · read to 2026-10-170 buys · 21 sells ($47M) — 3 selling insiders
- Last 180 days · read to 2026-10-170 buys · 21 sells ($47M) — 3 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-09-10. Based on Form 4 filings read through 2026-10-17; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about KIDS's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding KIDS as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 2,335,275
- Reported value $44,673,805
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 3 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about KIDS's institutional holders → See what each manager we track holds →
Short interest (FINRA)
KIDS had 929,989 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
KIDS had 3.56% of its shares outstanding sold short as of the 2026-09-30 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 5.54 days to cover at the same settlement.
- Reported short interest (shares) 929,989
- Short interest (% of shares outstanding) 3.56%
- Prior settlement (shares) 878,307
- Reported change 5.88%
- Days to cover (reported) 5.54
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Medtronic (MDT)
- Stryker (SYK)
- Zimmer Biomet (ZBH)
- Johnson & Johnson (JNJ)
- NuVasive (NUVA)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare KIDS vs…
Frequently asked questions
What does ORTHOPEDIATRICS CORP (KIDS) do?
OrthoPediatrics is a global medical device company that designs, develops, and markets a comprehensive portfolio of implants, instruments, and specialized braces for pediatric orthopedic conditions. The company operates through three primary segments—trauma and deformity correction, scoliosis, and sports medicine—and manages an extensive network of orthotic and prosthetic (O&P) clinics in the United States.
What sector is ORTHOPEDIATRICS CORP (KIDS) in?
ORTHOPEDIATRICS CORP (KIDS) is classified in the Health Care sector. Its industry is pediatric medical devices. It trades on NASDAQ.
Who are ORTHOPEDIATRICS CORP's (KIDS) competitors?
Notable peers of ORTHOPEDIATRICS CORP (KIDS) include Medtronic, Stryker, Zimmer Biomet, Johnson & Johnson and NuVasive. This peer set is informational only — not financial advice.
Is ORTHOPEDIATRICS CORP (KIDS) overbought or oversold right now?
ORTHOPEDIATRICS CORP (KIDS) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 62, in the neutral middle (as of 2026-10-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on KIDS come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.